Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma
Magali Chartier(Certara (United States)), Rhine R. Shen(Broad Institute), Thomas Peyret(Certara (United States)), Stephen B. Duffull(The University of Queensland), Simone Filosto(Kite (United States)), Jinghui Dong(Chinese PLA General Hospital), Daqin Mao(Tufts Medical Center), Justin A. Budka(Gilead Sciences (United Kingdom)), Saran Vardhanabhuti, Manoj Chiney(AbbVie (United States)), Michael Dodds(Certara (United States)), Andre Ndi(Certara (United States)), Francesca Milletti
Cited by 5
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
|New England Journal of Medicine|2023|437
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer
|Nature Genetics|2009|353